Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34,217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.
Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Gai X, Li Q, Liu W, Liu W, Yang X, Chen X, Lu J. Fu W, et al. Among authors: lu j. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e51-e58. doi: 10.1016/j.clml.2022.10.007. Epub 2022 Oct 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36402700 Free article. Clinical Trial.
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.
Weisel K, Doyen C, Dimopoulos M, Yee A, Lahuerta JJ, Martin A, Travers K, Druyts E, Toor K, Abildgaard N, Lu J, Van Droogenbroeck J, Geraldes C, Petrini M, Voillat L, Voog E, Facon T. Weisel K, et al. Among authors: lu j. Leuk Lymphoma. 2017 Jan;58(1):153-161. doi: 10.1080/10428194.2016.1177772. Epub 2016 Apr 28. Leuk Lymphoma. 2017. PMID: 27124703 Free article. Review.
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Hou J, et al. Among authors: lu j. J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4. J Hematol Oncol. 2017. PMID: 28683766 Free PMC article. Clinical Trial.
Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY, Wang GM, Chen Y, Casan J, Wolyncewicz G, Lin A, Poon LM, de Mel S, Koh LP, Tan LK, Ooi MG, Nagarajan C, Liu Y, Lai YY, Huang XJ, Spencer A, Gopalakrishnan SK, Lu J, Chng WJ. Soekojo CY, et al. Among authors: lu j. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470-e477. doi: 10.1016/j.clml.2019.04.011. Epub 2019 Apr 28. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31171473
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age.
Zhao P, Hou M, Liu Y, Liu HX, Huang RB, Yao HX, Niu T, Peng J, Jiang M, Han YQ, Hu JD, Zhou H, Zhou ZP, Qiu L, Zhang LS, Wang X, Wang HQ, Feng R, Yang LH, Ma LM, Wang SQ, Kong PY, Wang WS, Sun HP, Sun J, Zhou HB, Zhu TN, Wang LR, Zhang JY, Huang QS, Liu X, Fu HX, Li YY, Wang QF, Jiang Q, Jiang H, Lu J, Zhang XH. Zhao P, et al. Among authors: lu j. Platelets. 2021 Jul 4;32(5):633-641. doi: 10.1080/09537104.2020.1786042. Epub 2020 Jul 2. Platelets. 2021. PMID: 32614630 Free article.
Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).
Liu J, Hu X, Jia Y, Lu J, Lee JH, Kim K, Chen W, Liu A, Liu Y, Chen Q, Zhang C, Suh C, Kim MK, Zhou F, Chng WJ, Kumar SK, Durie B, Hou J, Fu W, Du J. Liu J, et al. Among authors: lu j. Leukemia. 2021 Jun;35(6):1797-1802. doi: 10.1038/s41375-020-01060-w. Epub 2020 Oct 20. Leukemia. 2021. PMID: 33082513 Free PMC article. No abstract available.
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X. Lu J, et al. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):e699-e709. doi: 10.1016/j.clml.2021.04.012. Epub 2021 Apr 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34108127 Free article. Clinical Trial.
34,217 results
You have reached the last available page of results. Please see the User Guide for more information.